|
|
|
| Effects of Serum CEA CA125 and Cyfra21-1 Levels on the Prognosis of Patients with Advanced NSCLC |
| LI Xueqin, ZHU Shuyang |
| Affiliated Hospital of Xuzhou Medical University, Jiangsu Xuzhou 221000, China |
|
|
|
|
Abstract Objective: To observe the correlation between serum CEA, CA125 and cytokeratin 19 fragment (cyfra21-1) levels and the survival of patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the application value of three tumor markers in the prognosis of patients with advanced NSCLC. Methods: The clinical characteristics, short-term efficacy and prognosis of 105 patients with stage III B and IV NSCLC treated in our hospital from January 2015 to June 2018 were retrospectively analyzed. Serum CEA, CA125 and Cyfra21-1 levels were measured before and after treatment. Results:There were significant differences in serum CEA, CA125 and Cyfra21-1 levels between adenocarcinoma and squamous cell carcinoma, stage III B and IV, and the number of extrapulmonary metastasis sites < 3 and < 3 (all P < 0.05). The levels of serum CEA, CA125 and Cyfra21-1 after treatment were significantly different from those before treatment (all P < 0.05); the progression-free survival (PFS) and total survival (OS) of patients with high-level indicators (CEA < 5 ng/ml, CA125 < 15 ng/ml, and Cyfra21-1 < 5 U/ml) were less than those of patients with low-level indicators (CEA < 5 ng/ml, CA125 < 15 ng/ml, Cyfra21-1 < 5 U/ml) (all P < 0.05). 05). Conclusion: Serum CEA, CA125 and Cyfra21-1 levels have high clinical value in judging the short-term therapeutic effect and prognosis of patients with advanced NSCLC.
|
|
|
|
|
|
[1] 罗聪聪,孟礼飞,鲍春荣.非小细胞肺癌免疫治疗最新临床进展[J].临床肺科杂志,2019,24(2):174~178,192.
[2] 杨兰平,黄汉生,陈慧华,等.非小细胞肺癌患者化疗前后血清CYFRA211、CEA、NSE、CA125、CA199水平的变化及临床意义[J].实用临床医药杂志,2014,18(17):40~43.
[3] 王海明,李志彬,齐学红,等.CT联合血清CEA、CA125、CYFRA21-1在非小细胞肺癌诊断中的应用研究[J].国际检验医学杂志,2018,39(20):2499~2503.
[4] 周际昌.实用肿瘤内科学[M].第2版.北京:人民卫生出版社,2003.152~153.
[5] 程越.肿瘤标志物在肺癌诊断、病理分型和临床分期中的价值探析[J].中国处方药,2016,22(12):148~150.
[6] Fiala O,Pesek M,Finek J,et al.Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib[J].Anticancer Res,2014,34(6):3205~3210.
[7] 张靖宇.CA153、CA125联合CEA检验在肺癌临床诊断中的价值探析[C].中国转化医学和整合医学研讨会(广州站).
[8] 王秋波,施雪峰,李巍,等.CEA、CYFRA21-1和CA125联合检测对非小细胞肺癌患者预后水平的评估价值[J].实用癌症杂志,2016,31(10):1601~1604.
[9] 王英,李佩章,刘金凤,等.血清HE4、NSE、CYFRA21-1检测在肺癌诊断及淋巴结转移监测中的价值[J].现代肿瘤医学,2019,27(1):67~70. |
|
|
|
2019, Vol. 25 
